ABSTRACT Objectives World Health Organization recommends a 7-drug 9–11-month
rifampicin-resistant tuberculosis (RR-TB) short treatment regimen (STR). To reduce the pill …

Background Multidrug-resistant tuberculosis (MDR-TB) patients have been suffering long,
ineffective, and toxic treatment until short-course injectable-free regimens emerged …

Background There is a need for short and safe all-oral treatment of rifampicin-resistant
tuberculosis. We compared outcomes up to 24 months after treatment initiation for patients …

Abstract Background Since 1 September 2016, bedaquiline and delamanid have been
administered for the treatment of patients with multidrug-resistant/rifampicin-resistant …

Background In 2020, WHO guidelines prioritised the use of a standard fully oral short
treatment regimen (STR) consisting of bedaquiline, levofloxacin or moxifloxacin …

Vietnam has been using a levofloxacin-based shorter treatment regimen (STR) for rifampicin
resistant/multidrug-resistant tuberculosis (RR/MDR-TB) patients since 2016 on a pilot basis …

Rationale: Improving treatment outcomes while reducing drug toxicity and shortening the
treatment duration to∼ 6 months remains an aspirational goal for the treatment of multidrug …

Background: The World health organization (WHO) recently recommended standardized all-
oral shorter regimens for rifampicin resistant Tuberculosis (RR-TB). For highly resistant …

Background After a history of poor treatments for rifampin-resistant tuberculosis (RR-TB),
recent advances have resulted in shorter, more effective treatments. However, they are not …

Objective Refractory rifampicin-resistant/multidrug resistant/extensively-drug resistant
tuberculosis (RR/MDR/XDR-TB) were defined as patients infected with Mycobacterium …